| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a defined pharmacological target as it is a chemical linker intermediate rather than a therapeutic agent. Its purpose is to serve as a building block for the construction of ADC linkers that connect cytotoxic payloads to monoclonal antibodies.
|
|---|---|
| ln Vitro |
No in vitro biological activity is reported for this compound, as it is a synthetic intermediate rather than a bioactive molecule. Its utility lies in its chemical reactivity for peptide coupling and linker synthesis.
|
| ln Vivo |
No in vivo activity is reported for this compound. It is not intended for direct therapeutic use but rather as a precursor in the synthesis of ADC components.
|
| Enzyme Assay |
Not applicable; this compound is a chemical intermediate and is not evaluated in pharmacological binding assays. Its characterization typically involves analytical methods such as NMR, HPLC, and mass spectrometry to confirm structure and purity.
|
| Cell Assay |
Not applicable; no cell-based assays are performed with this compound as a test article. It may be used indirectly in the synthesis of ADC linkers that are subsequently conjugated to antibodies for cell-based evaluation.
|
| Animal Protocol |
Not applicable; no animal studies are conducted with this compound as a primary test agent. It is used in the chemical synthesis of ADC components, which are then evaluated in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable for this compound, as it is a synthetic intermediate rather than a drug candidate.
|
| Toxicity/Toxicokinetics |
No toxicity data are reported for this compound. As a peptide-based linker intermediate, standard laboratory safety precautions should be followed. The compound is intended for research use only and is not for human use.
|
| References | |
| Additional Infomation |
Fmoc-Gly-Gly-Phe-Gly-NH-CH₂-O-CH₂COOH is a research chemical, not an approved drug. It is used in the development of ADCs, a class of targeted cancer therapeutics. The compound contains a Fmoc protecting group that can be removed to expose a reactive amine for conjugation to payloads, and a carboxylic acid for attachment to antibody scaffolds. It serves as a key intermediate in the synthesis of ADC linkers for targeted drug delivery. The compound is for research use only and not for human use.
|
| Molecular Formula |
C33H35N5O9
|
|---|---|
| Molecular Weight |
645.66
|
| Exact Mass |
645.243
|
| CAS # |
2264011-98-3
|
| PubChem CID |
142536946
|
| Appearance |
White to off-white solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
47
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)NCOCC(=O)O)NC(=O)CNC(=O)CNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
JOZGCSZISBFCOO-MHZLTWQESA-N
|
| InChi Code |
InChI=1S/C33H35N5O9/c39-28(16-36-33(45)47-18-26-24-12-6-4-10-22(24)23-11-5-7-13-25(23)26)34-17-30(41)38-27(14-21-8-2-1-3-9-21)32(44)35-15-29(40)37-20-46-19-31(42)43/h1-13,26-27H,14-20H2,(H,34,39)(H,35,44)(H,36,45)(H,37,40)(H,38,41)(H,42,43)/t27-/m0/s1
|
| Chemical Name |
2-[[[2-[[(2S)-2-[[2-[[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]methoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (154.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5488 mL | 7.7440 mL | 15.4880 mL | |
| 5 mM | 0.3098 mL | 1.5488 mL | 3.0976 mL | |
| 10 mM | 0.1549 mL | 0.7744 mL | 1.5488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
